Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 321.23 USD
Market Cap: 173B USD

EV/EBITDA
Enterprise Value to EBITDA

17.9
Current
13.8
Median
6.7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
17.9
=
Enterprise Value
215.8B USD
/
EBITDA
12.1B USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
Amgen Inc
NASDAQ:AMGN
Average EV/EBITDA: 41.4
17.9
11%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
171.3
N/A N/A
NL
argenx SE
XBRU:ARGX
62.3
807%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.8 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
10
2-Years Forward
EV/EBITDA
10.2
3-Years Forward
EV/EBITDA
10.3